Lu et al. developed a novel GPC3-IL7-CCL19-CAR-T cell that demonstrated significantly increased cytotoxicity against GPC3-positive HCC cells (e.g., HepG2), with a 1.5 to 2-fold higher killing efficiency compared to conventional GPC3-CAR-T cells[128]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.